Modified immune cells for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial is testing a new type of cell therapy for advanced kidney cancer that has not responded to standard treatments. The therapy takes your own immune cells, modifies them to target a protein called CD70 on the cancer cells, and gives them back to you to help fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced kidney cancer that has not responded to or has come back after at least one prior treatment.
- Your tumor is confirmed to have a protein called CD70 (this will be checked with a biopsy test).
- You must have at least one tumor that can be measured on a CT or MRI scan.
- Your major organs (liver, kidneys, lungs, heart) need to be working well enough, and you should be able to look after yourself (or need only minimal help).
- If you can become pregnant or father a child, you must agree to use effective birth control for at least one year after the infusion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests an experimental therapy using special immune cells engineered to target a protein called CD70 on kidney cancer cells. It may help patients whose cancer has returned or spread after previous treatment.
This early-stage trial tests a new type of cell therapy called CD70 CAR-T for advanced kidney cancer (clear cell renal cell carcinoma) that has spread or cannot be surgically removed. The therapy uses cells from your own immune system that are genetically modified to recognize and attack cancer cells.
This study tests a new cell-based treatment designed to target kidney cancer cells that have a protein called CD70. The treatment involves collecting your immune cells, modifying them in the lab, and infusing them back to fight the cancer. It's for patients with advanced kidney cancer who have already tried at least one standard immunotherapy.
This trial tests a special cell treatment (CAR-T) for people with immune-related kidney disease that has not responded to standard therapy. The treatment aims to remove faulty immune cells that damage the kidneys.
This trial tests an experimental treatment using your own immune cells, modified to attack cancer cells that have a specific marker called CD70. It's for people with advanced clear cell kidney cancer who have already tried standard treatments.
Hear when a new Advanced Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.